Polar Capital has raised its holding in the biotechnology company Hansa Biopharma to just over 11 million shares, up from just over 9.5 million. This brings its stake to the equivalent of 10.87 percent of the capital and voting rights.

This information was disclosed in a flagging notification.

According to Holdings' ownership data, Polar Capital first appeared in the shareholder list at the beginning of October.